KYTX (Kyverna Therapeutics) חוב לטווח קצר להון

The Kyverna Therapeutics (KYTX) price chart on the GURU.Markets platform reflects the asset's dynamics, with a value of 0.01. The brand is recognized as a leader in developing CAR-T therapies to combat autoimmune pathologies. Its growth strategy relies on academic partnerships and the expansion of its own development portfolio without mergers. While high-tech cell synthesis is automated, tissue collection remains the prerogative of qualified medical professionals.

For the biotech sector company Kyverna Therapeutics (KYTX), which focuses on scalable cell therapy, the short-term debt-to-equity ratio reflects the balance between expansion and financial stability. This metric is calculated as the ratio of current liabilities with a maturity of up to one year to total equity. The current value of 0.01 demonstrates the company's degree of reliance on rapid refinancing. A decrease in this ratio confirms solvency and minimizes bankruptcy risk during the platform's development.